SCHEMBL4415216

SCHEMBL4415216

COc1cc2c(c(OC)c1)C(c1ccc(-c3ccccc3)cc1)N(C(=O)c1ccc(OC(F)(F)F)cc1)CC2

nearest known ligand 0.55

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GRIN2C Q14957 4/20 0.55
CA12 O43570 3/20 0.50
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA7 P43166 3/20 0.50
CA9 Q16790 3/20 0.50
CA14 Q9ULX7 3/20 0.50
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
MTNR1B P49286 1/20 0.46
PDE4B Q07343 2/20 0.45
ABCG2 Q9UNQ0 2/20 0.45
PDE4D Q08499 1/20 0.45
PPIB P23284 1/20 0.45
PPIA P62937 1/20 0.45
LMNA P02545 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
ABCB1 P08183 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4552564 0.92 GRIN2C (0.64) GRIN2CCA12CA1CA2CA7
SCHEMBL4414785 0.90 GRIN2C (0.54) GRIN2CCA12CA1CA2CA7
SCHEMBL4418256 0.89 KMT2A (0.52) GRIN2CCA12CA1CA2CA7
SCHEMBL4423052 0.88 GRIN2C (0.57) GRIN2CCA12CA1CA2CA7
SCHEMBL4414441 0.88 GRIN2C (0.54) GRIN2CCA12CA1CA2CA7
SCHEMBL4422046 0.87 GRIN2C (0.51) GRIN2CCA12CA1CA2CA7
SCHEMBL4413447 0.87 KMT2A (0.55) GRIN2CCA12CA1CA2CA7
SCHEMBL4422031 0.84 KMT2A (0.56) GRIN2CCA12CA1CA2CA7
SCHEMBL4416142 0.83 GRIN2C (0.55) GRIN2CKMT2AMEN1MTNR1BPDE4B
SCHEMBL13973320 0.83 GRIN2C (0.54) GRIN2CCA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1663983-B1 N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS 4SC AG (DE) 2009-01-21 EP disclosed
EP-1663983-A1 N-SUBSTITUTED, 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS 4SC AG (DE) 2006-06-07 EP disclosed
US-20050070570-A1 Novel potassium channels modulators 4SC AG (DE) 2005-03-31 US disclosed
WO-2004113302-A1 N-SUBSTITUTED 6,8-DIALKOXY-1,2,3,4-TETRAHYDRO-1H-ISOQUINOLINE AS POTASSIUM CHANNELS MODULATORS 4SC AG (DE) 2004-12-29 WO disclosed
EP-1489071-A1 N-substituted, 3,4-dihydro-1H-isoquinoline as potassium channels modulators 4SC AG (DE) 2004-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070570-A1 Novel potassium channels modulators HCN4, KCNA4, KCNN4 GRIN2C 567/4885CA12 2330/4885CA1 2370/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.